

- (3) None.  
(4) None.

This statement is made as of February 2, 1972.

Dated: February 2, 1972.

LEROY J. SCHULTZ.

[FR Doc.72-4173 Filed 3-17-72;8:48 am]

### WILLARD B. SIMONDS

#### Statement of Changes in Financial Interests

In accordance with the requirements of section 710(b) (6) of the Defense Production Act of 1950, as amended, and Executive Order 10647 of November 28, 1955, the following changes have taken place in my financial interests during the past 6 months:

- (1) No change.
- (2) No change.
- (3) No change.
- (4) No change.

This statement is made as of January.

Dated: January 31, 1972.

WILLIAM B. SIMONDS.

[FR Doc.72-4174 Filed 3-17-72;8:48 am]

### STANLEY M. SWANSON

#### Statement of Changes in Financial Interests

In accordance with the requirements of section 710(b) (6) of the Defense Production Act of 1950, as amended, and Executive Order 10647 of November 28, 1955, the following changes have taken place in my financial interests during the past 6 months:

- (1) No change.
- (2) No change.
- (3) No change.
- (4) No change.

This statement is made as of March 6, 1972.

Dated: March 6, 1972.

STANLEY M. SWANSON.

[FR Doc.72-4175 Filed 3-17-72;8:48 am]

### CHARLES W. WATSON

#### Statement of Changes in Financial Interests

In accordance with the requirements of section 710(b) (6) of the Defense Production Act of 1950, as amended, and Executive Order 10647 of November 28, 1955, the following changes have taken place in my financial interests during the past 6 months:

- (1) No change.
- (2) No change.
- (3) No change.
- (4) No change.

This statement is made as of February 1, 1972.

Dated: February 1, 1972.

CHARLES W. WATSON.

[FR Doc.72-4176 Filed 3-17-72;8:48 am]

## DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

### Food and Drug Administration

#### AMERICAN CYANAMID CO.

#### Notice of Filing of Petition for Food Additive

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409 (b) (5), 72 Stat. 1786; 21 U.S.C. 348(b) (5)), notice is given that a petition (FAP 2B2763) has been filed by American Cyanamid Co., Wayne, N.J. 07470 proposing that § 121.2571 *Components of paper and paperboard in contact with dry food* (21 CFR 121.2571) be amended to provide for the safe use of acrylamide, N-(dimethylaminemethyl) acrylamide, styrene terpolymer as a dry-strength agent in paper and paperboard intended for contact with dry food.

Dated: March 10, 1972.

VIRGIL O. WODICKA,  
Director, Bureau of Foods.

[FR Doc.72-4146 Filed 3-17-72;8:45 am]

[Docket No. FDC-D-362; NDA 11-253, etc.]

### CERTAIN DRUGS CONTAINING VALETHAMATE BROMIDE

#### Notice of Withdrawal of Approval of New Drug Applications

A notice was published in the FEDERAL REGISTER of October 9, 1971 (36 F.R. 19710), extending to Ayerst Laboratories, Division of American Home Products Corp., 685 Third Avenue, New York, NY 10017, and to any interested person who may be adversely affected, an opportunity for hearing on the proposal of the Commissioner of Food and Drugs to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act, withdrawing approval of the following new-drug applications and all amendments and supplements thereto. The basis of the proposed action was the lack of substantial evidence that the drugs are effective for their labeled indications. The drugs are no longer marketed.

NDA 11-253; Murel Tablets containing valethamate bromide.

NDA 11-989; Murel S.A. Tablets containing valethamate bromide.

NDA 11-290; Murel with Phenobarbital Tablets containing valethamate bromide and phenobarbital.

NDA 11-998; Murel with Phenobarbital S.A. Tablets containing valethamate bromide and phenobarbital.

NDA 11-263; Murel Injection containing valethamate bromide.

Neither the holder of the new-drug applications nor any other interested person have filed a written appearance of election as provided by said notice. The failure to file such an appearance is construed as an election by such persons not to avail themselves of an opportunity for hearing.

The Commissioner of Food and Drugs, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act 505(e), 52 Stat. 1053, as amended; 21 U.S.C. 355(e) and under authority delegated to him (21 CFR 2.120), finds that on the basis of new information before him with respect to each of said drugs, evaluated together with the evidence available to him when each application was approved, there is a lack of substantial evidence that each of the drugs will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

Therefore, pursuant to the foregoing finding, approval of the above-listed new-drug applications and all amendments and supplements thereto is withdrawn effective on the date of publication hereof in the FEDERAL REGISTER (3-18-72).

Dated: March 10, 1972.

SAM D. FINE,  
Associate Commissioner  
for Compliance.

[FR Doc.72-4147 Filed 3-17-72;8:45 am]

[Docket No. FDC-D-445, NDA 0-723, etc.]

### S. E. MASSENGILL CO., ET AL.

#### New-Drug Applications; Notice of Withdrawal of Approval

The holders of the new-drug applications listed herein have not submitted annual reports of experience with the drugs as required and have advised the Food and Drug Administration that the new drugs involved were never marketed or marketing has been discontinued and have requested withdrawal of approval of the new-drug applications, thereby waiving opportunity for a hearing.

Therefore pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505(e), 52 Stat. 1053, as amended; 21 U.S.C. 355(e)), and under authority delegated to the Commissioner (21 CFR 2.120), approval of the following new-drug applications, including all amendments and supplements thereto, is hereby withdrawn on the grounds that the applicants have failed to make reports under section 505(j) of the Act (21 U.S.C. 355(j) and §§ 130.13 and 130.35 (e) and (f) of the new-drug regulations (21 CFR 130.13 and 130.35).

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. D-72-161]

### ASSISTANT SECRETARY AND DEPUTY ASSISTANT SECRETARY FOR COMMUNITY DEVELOPMENT

#### Delegation of Authority With Respect to Open-Space Land

The delegation of authority to the Assistant Secretary for Community Development, effective March 8, 1971 (36 F.R. 5004, March 16, 1971), is amended as follows:

Section A, subsection 6 is revised to read:

6. Open-Space Land Program under title VII of the Housing Act of 1961 (42 U.S.C. 1500-1500d-1), provided that the conversion of land involving historic or architectural purposes under section 705 (42 U.S.C. 1500c-1) has prior approval of the Secretary of the Interior.

(Sec. 7(d), Department of Housing and Urban Development Act, 42 U.S.C. 3535(d))

*Effective date.* This delegation of authority is effective as of July 1, 1971.

GEORGE ROMNEY,  
Secretary of Housing and  
Urban Development.

[FR Doc.72-4186 Filed 3-17-72; 8:49 am]

[Docket No. D-72-162]

### REGIONAL ADMINISTRATORS ET AL.

#### Redelegation of Authority With Respect to Open-Space Land Program

SECTION A. *Authority redelegated.* 1. Each Regional Administrator, Deputy Regional Administrator, Area Director, and Deputy Area Director of the Department of Housing and Urban Development is authorized with respect to the Open-Space Land Program under title VII of the Housing Act of 1961 (42 U.S.C. 1500-1500d-1) to (a) authorize grants and establish the terms thereof; (b) execute agreements for grants and amendments thereto; and (c) approve requisitions for funds and third-party contracts except as provided under section B.

2. Each Area Operations Division Director, and Deputy Area Operations Division Director is authorized with respect to the Open-Space Land Program under title VII of the Housing Act of 1961 (42 U.S.C. 1500-1500d-1) to (a) execute agreements for grants and amendments thereto; and (b) approve requisitions for funds and third-party contracts.

SEC. B. *Authority excepted.* There is excepted from the authority delegated under section A the authority to approve the conversion or interim use of open-space land for other than open-space purposes, or the transfer of interest in open-space land, under sections 702(c), 704, 705 of the Housing Act of 1961.

SEC. C. *Authority to approve the conversion or interim use of open-space land for other than open-space purposes, or the transfer of interest in open-space*

*land.* Each Regional Administrator and Deputy Administrator is authorized to approve the conversion or interim use of open-space land for other than open-space purposes, or the transfer of interest in open-space land under sections 702(c), 704, 705 of the Housing Act of 1961 (42 U.S.C. 1500a(c), 1500c, 1500c-1), except that the conversion under section 705 or the transfer or interim use of land under section 702(c) involving historic or architectural purposes must have prior approval of the Secretary of the Interior.

SEC. D. *Authority to approve transfers of interest in open-space land.* Each Area Director, and Deputy Area Director is authorized to approve the transfer of interests in open-space land to other uses under section 702(c) of the Housing Act of 1961: *Provided,* That the transfer of interests in land involving historic or architectural purposes shall not be inconsistent with the historic or architectural purposes of such open-space land.

SEC. E. *Redelegation to Region VIII (Denver) official.* The Assistant Regional Administrator for Community Development in Region VIII (Denver) is authorized to exercise the power and authority delegated in this document to Area Directors and Deputy Area Directors.

SEC. F. *Exercise of redelegated authority.* Redelegations of authority made under sections A, B, C, D, and E shall not be construed to modify or otherwise affect the administration and supervisory powers of the Regional Administrator and Deputy Regional Administrator to whom a delegate is responsible, and these supervisors shall, in addition to any other authority delegated to them, have the same final authority redelegated to their subordinates.

(Secretary's delegation of authority being published concurrently with this redelegation; Secretary's delegation, sec. D, 36 F.R. 5004, Mar. 16, 1971)

*Effective date.* This redelegation of authority shall be effective as of July 1, 1971.

JOHN A. NEVIUS,  
Deputy Assistant Secretary  
for Community Development.

[FR Doc.72-4187 Filed 3-17-72; 8:49 am]

## ATOMIC ENERGY COMMISSION

[Docket No. 50-301]

### WISCONSIN ELECTRIC POWER CO. AND WISCONSIN MICHIGAN POWER CO.

#### Order of the Board Changing Location of Hearing

In the matter of Wisconsin Electric Power Co. and Wisconsin Michigan Power Co., Point Beach Nuclear Plant, Unit 2.

The location for the evidentiary hearing in the above captioned matter is being changed from Manitowoc, Wis., to Milwaukee, Wis. The evidentiary hearing will reconvene on March 21, 1972, at 10 a.m., local time, at the following location:

NDA No.	Drug name	Applicant's name and address
0-723	Bethiamin Elixir (thiamine hydrochloride).	The S. E. Massengill Co., 527 Fifth St., Bristol, TN 37620.
1-408	Rabellon Tablets (hyoscyamine hydrobromide, atropine sulfate, scopolamine hydrobromide).	Merck Sharp & Dohme, Sunningtown Pike, West Point, Pa. 19486.
1-735	Elixol Liquid (rhubarb root).	John T. Lloyd Labs, Westerfield Laboratories Inc., 3941 Brotherton Rd., Cincinnati, OH 45209.
2-691	Bloden B; Elixir (thiamine hydrochloride).	Cooper Laboratories Inc., Fairfield Rd., Wayne, N.J. 07470.
2-854	Histamine Diphosphate Injection (histamine diphosphate).	Abbott Laboratories, North Chicago, Ill. 60064.
3-807	Magsal Suspension (magnesium trisilicate, aluminum hydroxide).	Endo Laboratories, Inc., 1000 Stewart Ave., Garden City, NY 11530.
6-866	Dibulnine Sulfate Injection (dibutoline sulfate).	Merck Sharp & Dohme, Sunningtown Pike, West Point, Pa. 19486.
7-908	Carbo Resin Powder (carbocrylamine resins).	Eli Lilly & Co., Box 618, Indianapolis, IN 46206.
8-397	Wyamine Sulfate Elixir (mephentermine sulfate).	Wyeth Laboratories, Inc., Box 8200, Philadelphia, PA 19101.
10-360	Reserpine Tablets (reserpine).	Halsey Drug Co., Inc., 1327 Pacific St., Brooklyn, NY 11233.
10-409	Rauwolfia Serpentina Tablets (rauwolfia serpentina).	Do.
11-118	Raurethritol Tablets (pentaerythritol tetranitrate, reserpine).	Bowman Pharmaceuticals, Inc., 119 Schroyer Ave., SW., Canton, OH 44702.
12-847	Fortizyme Tablets (alpha amylase).	Breon Laboratories, Inc., 90 Park Ave., New York, NY 10016.

This order shall become effective on its date of publication in the FEDERAL REGISTER (3-18-72).

Dated: March 10, 1972.

SAM D. FINE,  
Associate Commissioner  
for Compliance.

[FR Doc.72-4148 Filed 3-17-72; 8:45 am]

## NATIONAL FISH MEAL & OIL ASSOCIATION

### Notice of Filing of Petition for Food Additive

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786; 21 U.S.C. 348(b)(5)), notice is given that a petition (FAP 2A2762) has been filed by the National Fish Meal & Oil Association, 1225 Connecticut Avenue NW., Washington, DC 20036, proposing that § 121.1202 *Whole fish protein concentrate* (21 CFR 121.1202) be amended to provide for the safe use of whole fish protein concentrate as a food supplement in manufactured foods.

Dated: March 10, 1972.

VIRGIL O. WODICKA,  
Director, Bureau of Foods.

[FR Doc.72-4149 Filed 3-17-72; 8:46 am]